Navigation Links
GeneNews to exhibit ColonSentry(TM) at Family Medicine Forum 2008
Date:11/26/2008

TORONTO, Nov. 26 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will be exhibiting at the Family Medicine Forum 2008 being held at the Sheraton Centre in Toronto from November 27th to November 29th, 2008. GeneNews' exhibit, at booth # 400, will feature the Company's lead product, ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer.

"This event, which attracts more than 1500 family physicians and healthcare professionals, is the premier family medicine conference in Canada and the ideal audience to increase the awareness of ColonSentry(TM) in Canada," said Gailina Liew, Chief Operating Officer of GeneNews. "Building on the expanded roll out of ColonSentry(TM) at additional locations in the Greater Toronto Area last week, our exhibition at the Family Medicine Forum will further support our Canadian commercialization strategy as we plan to offer ColonSentry(TM) in other regions of Canada throughout 2009."

The Family Medicine Forum combines the Annual Scientific Assemblies of the College of Family Physicians of Canada (CFPC), the Ontario College of Family Physicians (OCFP), and the Annual Workshops of the CFPC's Sections of Teachers and Researchers. For additional information please visit ww.fmf.cfpc.ca.

    About GeneNews
    --------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. GeneNews restructures operations
4. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
5. GeneNews Announces Second Quarter Results
6. GeneNews launches worlds first blood test for colorectal cancer screening
7. GeneNews announces management changes to support commercialization of ColonSentry(TM)
8. Genenews adds two members to its Board of Directors
9. GeneNews Announces First Quarter Results
10. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
11. GeneNews announces 2007 year end results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):